英国胃肠病学会/英国PBC原发性胆汁性胆管炎治疗与管理指南
该指南由英国胃肠病学会与UK-PBC制定,涵盖原发性胆汁性胆管炎的诊断、风险分层与治疗。所有患者起始熊去氧胆酸(UDCA)治疗,应答不佳者(碱性磷酸酶>1.67倍正常上限和/或胆红素升高)考虑二线治疗,奥贝胆酸(OCA)是唯一获NICE推荐的药物;随访需终身进行并管理症状。
要点
- 所有PBC患者起始UDCA治疗,基于基线与治疗中因素进行风险分层。
- UDCA不耐受或治疗失败(ALP>1.67×ULN和/或胆红素升高)者考虑二线治疗。
- OCA是唯一获NICE推荐的二线药物;随访终身,需同时管理疾病进展与症状。
核心结论
- PBC管理需终身同时针对疾病进展与症状负担,所有患者起始UDCA,应答不佳者考虑二线治疗。
研究设计与样本
- 英国胃肠病学会/UK-PBC制定的原发性胆汁性胆管炎治疗与管理指南。
主要发现
- 男性、发病年龄<45岁及就诊时晚期疾病是结局较差的基线预测因素。
- 大多数就诊患者无肝硬化,因联合胆汁淤积性肝试验与抗线粒体抗体诊断日益增多。
- UDCA治疗失败常表现为碱性磷酸酶>1.67倍正常上限和/或胆红素升高。
关键数值与推荐
- 所有患者起始UDCA治疗并进行风险分层。
- UDCA不耐受或治疗失败者应考虑二线治疗,OCA是唯一获NICE推荐的药物。
- 随访需终身进行,涵盖疾病治疗与相关症状管理。
临床怎么用
- 所有PBC患者起始UDCA,基于基线与治疗中因素(尤其治疗应答)进行风险分层。
- UDCA不耐受或UDCA治疗失败者考虑二线治疗,OCA为唯一获NICE推荐的二线药物。
- 对患者终身随访,同时管理疾病进展与相关症状。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (<45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase >1.67 × upper limit of normal and/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.
引用
- Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018. PMID: 29593060. doi:10.1136/gutjnl-2017-315259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。